"
Team:Paris Bettencourt/Project/Overview
From 2013.igem.org
| Line 67: | Line 67: | ||
<div class="rightparagraph"> | <div class="rightparagraph"> | ||
<p><b> | <p><b> | ||
| - | Using <em>Escherichia coli</em> as a model organism we are developing | + | Using <em>Escherichia coli</em> as a model organism we are developing approaches that could lead to eradication of tuberculosis. A drug screen aimed for a specific mycobacterial metabolic pathway, a biosensor for detection of sequence specific antibiotic resistance, a synthetic <em>E. coli</em> which could invade macrophages and kill mycobacteria, and finally a phage carrying sRNA which silence the production of antibiotic resistance proteins thus making antibiotic treatment more effective. |
</b></p> | </b></p> | ||
</div> | </div> | ||
Revision as of 16:00, 3 October 2013
<body>
Using Escherichia coli as a model organism we are developing approaches that could lead to eradication of tuberculosis. A drug screen aimed for a specific mycobacterial metabolic pathway, a biosensor for detection of sequence specific antibiotic resistance, a synthetic E. coli which could invade macrophages and kill mycobacteria, and finally a phage carrying sRNA which silence the production of antibiotic resistance proteins thus making antibiotic treatment more effective.
Infiltrate
A more efficient treatment of TB should contain a drug which rapidly kills mycobacteria and a delivery system for such drug, which could enable the killing of mycobacteria inside the infected macrophages. In our system the rapid drug is Trehalose Dimycolate Hydrolase (TDMH), while the delivery system is LLO carrying strain of E. coli.
+33 1 44 41 25 22/25
team2013@igem-paris.org 
